These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35092134)

  • 1. N-glycosylation regulates MET processing and signaling.
    Saitou A; Hasegawa Y; Fujitani N; Ariki S; Uehara Y; Hashimoto U; Saito A; Kuronuma K; Matsumoto K; Chiba H; Takahashi M
    Cancer Sci; 2022 Apr; 113(4):1292-1304. PubMed ID: 35092134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
    Miao W; Sakai K; Sato H; Imamura R; Jangphattananont N; Takagi J; Nishita M; Minami Y; Matsumoto K
    Cancer Sci; 2019 Oct; 110(10):3340-3349. PubMed ID: 31342590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-glycan on N262 of FGFR3 regulates the intracellular localization and phosphorylation of the receptor.
    Hashimoto U; Fujitani N; Uehara Y; Okamoto H; Saitou A; Ito F; Ariki S; Shiratsuchi A; Hasegawa Y; Takahashi M
    Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130565. PubMed ID: 38244702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and Characterization of a Chinese Hamster Ovary Heparan Sulfate Cell Mutant Defective in Both Met Receptor Binding and Hepatocyte Growth Factor NK1/Met Signaling.
    Cao T; Pan J; Li X; He Y; Jiang Y; Chang Y; Zhang Q; Lan Y; Wang H; Jiao W; Tian Z; Zhang L
    Cell Physiol Biochem; 2018; 48(4):1480-1491. PubMed ID: 30107380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
    Kirchhofer D; Yao X; Peek M; Eigenbrot C; Lipari MT; Billeci KL; Maun HR; Moran P; Santell L; Wiesmann C; Lazarus RA
    J Biol Chem; 2004 Sep; 279(38):39915-24. PubMed ID: 15218027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple biological responses are induced by glycosylation-deficient hepatocyte growth factor.
    Fukuta K; Matsumoto K; Nakamura T
    Biochem J; 2005 Jun; 388(Pt 2):555-62. PubMed ID: 15693751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.
    Landgraf KE; Santell L; Billeci KL; Quan C; Young JC; Maun HR; Kirchhofer D; Lazarus RA
    J Biol Chem; 2010 Dec; 285(51):40362-72. PubMed ID: 20937841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
    Comoglio PM
    EXS; 1993; 65():131-65. PubMed ID: 8380735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains.
    Holmes O; Pillozzi S; Deakin JA; Carafoli F; Kemp L; Butler PJ; Lyon M; Gherardi E
    J Mol Biol; 2007 Mar; 367(2):395-408. PubMed ID: 17258232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
    Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 17. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress of HGF/MET signaling pathway in EGFR-TKI resistance 
in non-small cell lung cancer].
    Song S; Bi M
    Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):755-9. PubMed ID: 25342043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.
    Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P
    J Biol Chem; 2008 Jul; 283(30):21267-77. PubMed ID: 18495663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.
    Peek M; Moran P; Mendoza N; Wickramasinghe D; Kirchhofer D
    J Biol Chem; 2002 Dec; 277(49):47804-9. PubMed ID: 12372819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.